Market news — every asset we track

Assets

BNR

Burning Rock Biotech Posts Q2 2026 Revenue Decline but Advances Fast-Track Reviews for Oncology NGS Kits

Detailed price information for Burning Rock Biotech Ltd ADR (BNR-Q) from The Globe and Mail including charting and trades.

Sep 11The Globe and Mail

BNR

Burning Rock Reports Second Quarter 2026 Financial Results

GUANGZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2026. Recent Business Updates Therapy Selection & MRD OncoScreen® BCMatch Tissue Kit has officially entered the Priority Review Channel of the Center for Medical Device Evaluation (

Sep 10Yahoo Finance

BNR

Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook Amid Prenatal Test Weakness

Aug 2Yahoo Finance

BNR

MYGN

This is the newest page. Registered accounts read further back.